Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
103 hedge funds and large institutions have $594M invested in Epizyme, Inc in 2015 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 38 increasing their positions, 18 reducing their positions, and 10 closing their positions.
210% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 10
111% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 18
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
78% more call options, than puts
Call options by funds: $653K | Put options by funds: $366K
33% more capital invested
Capital invested by funds: $448M → $594M (+$147M)
26% more funds holding
Funds holding: 82 → 103 (+21)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$39.4M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$32.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$20.1M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$17.3M |
| 5 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$9.93M |
| 2 |
PA
Perceptive Advisors
New York
|
-$8.16M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$8.08M |
| 4 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$5.16M |
| 5 |
Millennium Management
New York
|
-$3.4M |
EPZM Hedge Fund Activity: Q1 2015 in Review
103 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q1 2015, worth a combined $594M — up 33% from $448M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new EPZM positions and 10 closed out — a net gain of 21 holders — while 38 added to existing stakes and 18 trimmed.
The largest buyer was Primecap Management, adding an estimated $39.4M. The largest seller was Emerald Advisers, cutting an estimated $9.93M.
- 103 institutional investors held Epizyme, Inc (EPZM) as of Q1 2015, up from 82 in Q4 2014.
- Funds reported $594M of Epizyme, Inc stock for Q1 2015, up 33% quarter-over-quarter.
- 31 funds opened new Epizyme, Inc positions in Q1 2015 and 10 closed out, a net change of +21 holders.
- The largest Epizyme, Inc buyer in Q1 2015 was Primecap Management, an estimated $39.4M added.
- The largest Epizyme, Inc seller in Q1 2015 was Emerald Advisers, an estimated $9.93M sold.
Based on aggregated 13F filings for Q1 2015.